This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Biguanide
DrugBank Accession Number
DB13100
Background

Biguanide has been investigated for the treatment of Diabetes Mellitus.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 101.113
Monoisotopic: 101.070145245
Chemical Formula
C2H7N5
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as biguanides. These are organic compounds containing two N-linked guanidines.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Guanidines
Direct Parent
Biguanides
Alternative Parents
Carboximidamides / Organopnictogen compounds / Imines / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Biguanide / Carboximidamide / Hydrocarbon derivative / Imine / Organopnictogen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
guanidines (CHEBI:3095)
Affected organisms
Not Available

Chemical Identifiers

UNII
FB4Q52I9K2
CAS number
56-03-1
InChI Key
XNCOSPRUTUOJCJ-UHFFFAOYSA-N
InChI
InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)
IUPAC Name
carbamimidamidomethanimidamide
SMILES
NC(=N)NC(N)=N

References

General References
Not Available
KEGG Compound
C07672
PubChem Compound
5939
PubChem Substance
347829224
ChemSpider
5726
RxNav
1918319
ChEBI
3095
ZINC
ZINC000004097424
Wikipedia
Biguanide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentAtherosclerosis / Diabetes / Restenosis1
3CompletedTreatmentDiabetes Mellitus1
3CompletedTreatmentDisorder of Glucose Regulation / Polycystic Ovarian Syndrome (PCOS)1
3CompletedTreatmentType 2 Diabetes Mellitus3
3RecruitingTreatmentDiabetes Mellitus / Endocrine System Diseases / Hypoglycemic Agents / Metabolic Diseases / Metabolism Disorder, Glucose / Type 2 Diabetes Mellitus1
2RecruitingTreatmentImpaired Glucose Tolerance / Insulin Sensitivity / Metabolism Disorder, Glucose1
2TerminatedTreatmentAdenocarcinoma of Lung (Disorder) / Non-Small Cell Lung Carcinoma (NSCLC)1
2WithdrawnTreatmentProstate Cancer1
1Active Not RecruitingTreatmentEarly Breast Cancer / Neoplasms, Breast / Stage 0 Breast Carcinoma / Stage II Breast Carcinoma / Stage III Breast Carcinoma1
1Unknown StatusTreatmentNeoplasms, Brain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.81 mg/mLALOGPS
logP-2.1ALOGPS
logP-1.5ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)19.2ChemAxon
pKa (Strongest Basic)12.06ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area111.77 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity46.57 m3·mol-1ChemAxon
Polarizability9.4 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 21, 2016 03:05 / Updated at June 12, 2020 16:53